U.S. Markets open in 31 mins

ICU Medical Inc (ICUI) Files 10-K for the Fiscal Year Ended on December 31, 2018

- By insider

ICU Medical Inc (ICUI) files its latest 10-K with SEC for the fiscal year ended on December 31, 2018. ICU Medical Inc is engaged in the development, manufacture and sale of medical devices used in infusion therapy, oncology and critical care applications. Its products include needlefree connectors, nanoclave, chemoclock, chemoclave, and among others. ICU Medical Inc has a market cap of $5.17 billion; its shares were traded at around $252.46 with a P/E ratio of 191.26 and P/S ratio of 3.81. ICU Medical Inc had annual average EBITDA growth of 7.50% over the past ten years. GuruFocus rated ICU Medical Inc the business predictability rank of 2.5-star.

For the last quarter ICU Medical Inc reported a revenue of $340.4 million, compared with the revenue of $370.1 million during the same period a year ago. For the latest fiscal year the company reported a revenue of $1.4 billion, an increase of 8.3% from last year. For the last five years ICU Medical Inc had an average revenue growth rate of 40.4% a year.

The reported diluted earnings per share was $1.33 for the year, a decline of 59.6% from the previous year. Over the last five years ICU Medical Inc had an average EPS decline of 3.2% a year. The ICU Medical Inc had a decent operating margin of 12.04%, compared with the operating margin of 4.87% a year before. The 10-year historical median operating margin of ICU Medical Inc is 16.62%. The profitability rank of the company is 8 (out of 10).

At the end of the fiscal year, ICU Medical Inc has the cash and cash equivalents of $344.8 million, compared with $290.1 million in the previous year. The company had no long term debt. The interest coverage to the debt is at a comfortable level of 237.8. ICU Medical Inc has a financial strength rank of 9 (out of 10).

At the current stock price of $252.46, ICU Medical Inc is traded at 28.6% premium to its historical median P/S valuation band of $196.36. The P/S ratio of the stock is 3.81, while the historical median P/S ratio is 2.96. The intrinsic value of the stock is $16.25 a share, according to GuruFocus DCF Calculator. The stock gained 13.16% during the past 12 months.

For the complete 20-year historical financial data of ICUI, click here.

This article first appeared on GuruFocus.